Stockholm, December 21, 2023 – Intervacc AB (publ) announces that the company and the chairman of the board have been informed that Ulrika Enhörning, appointed by Swedbank Robur Fonder and Thomas Ehlin, appointed by ... Read more
Stockholm, December 11, 2023 – European experts on strangles, a highly contagious and serious infectious disease affecting horses, will on December 13th meet at the National Equestrian Centre at Flyinge to share ... Read more
Stockholm, November 23, 2023 - Intervacc AB (publ) has at the request of a group of shareholders, which together control not less than one-tenth of all shares in the company, on 23 November 2023 held an Extraordinary ... Read more
Stockholm, November 22, 2023 – Intervacc AB (“Intervacc”) announces that the United States Patent and Trademark Office has granted an approval for Intervacc’s patent application in the United States for a vaccine ... Read more
Sales of Strangvac® are still low, but higher sales have been noted in recent months.
The Group in summary
The composition of the Nomination Committee has been determined, Intervacc announced today that the Nomination Committee consists of the following persons who together represent approximately 16,6 percent of the number ... Read more